UAB and partners launch the PREVeNT study, aimed at preventing the onset of seizures in children with tuberous sclerosis.

Preliminary results from UAB’s CBD oil studies show benefit in seizure control in some patients.
More evidence that generic medications are as effective as brand name drugs.
Best of 2015A new surgical robot helps UAB physicians add a new technique for preparing for epilepsy surgery.

Published in Focus on Patient Care
Best of 2015 2The UAB studies are designed to test the safety and tolerability of CBD oil in patients with intractable seizures. CBD oil, a derivative of the cannabis plant, is delivered orally as an oily liquid.
Published in Focus on Patient Care
A multisite study led by UAB has found the first biomarker for the onset of seizures in infants with tuberous sclerosis.
A UAB study sheds new light on the epigenetics of memory formation and memory loss in patients with epilepsy, and the discovery may have implications for many other memory disorders.

Best of 2014 2

The first patient in the Southeast to get the RNS responsive neurostimulation seizure-control device implanted in the brain reports dramatic results at UAB.

Published in Focus on Patient Care
UAB is the first medical center in the Southeast to implant a new type of electrical stimulator to control seizures in patients with epilepsy.
UAB’s Epilepsy Center is housed in the Department of Neurology under the direction of Jerzy Szaflarski, M.D., Ph.D.
Published in Focus on Patient Care
Back to Top